BBIO
BridgeBio Pharma Inc.
$67.04
-$2.08(-3.01%)
44
Overall
40
Value
40
Tech
52
Quality
Market Cap
$12.92B
Volume
1.25M
52W Range
$31.77 - $84.94
Target Price
$104.45
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | $40.6M | $8.2M | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M | ||
| Total Revenue | $40.6M | $8.2M | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | -- | -- | $3.1M | $3.4M | $2.4M | $3.9M | $21.0M | ||
| GROSS PROFIT | |||||||||
| Gross Profit | $40.6M | $8.2M | $66.6M | $74.2M | $6.9M | $218.0M | $481.1M | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $306.8M | $482.7M | $643.2M | $542.7M | $606.3M | $795.4M | $983.2M | ||
| Research & Development | $209.9M | $337.0M | $451.0M | $399.5M | $455.7M | $506.5M | $452.0M | ||
| Research Expense | $209.9M | $337.0M | $451.0M | $399.5M | $455.7M | $506.5M | $452.0M | ||
| Selling, General & Administrative | $94.4M | $145.7M | $192.2M | $143.2M | $150.6M | $288.9M | $531.2M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | $21.5M | -- | ||
| General & Administrative Expenses | $94.4M | $145.7M | $192.2M | $143.2M | $150.6M | $288.9M | $531.2M | ||
| Depreciation & Amortization | -- | -- | $3.3M | $4.1M | $4.1M | $3.7M | -- | ||
| Depreciation & Amortization | -- | -- | $3.3M | -- | -- | -- | -- | ||
| Amortization | -- | -- | $48.3M | $32.3M | $30.0M | $27.7M | -- | ||
| Other Operating Expenses | $-2.5M | $-5.1M | $-5.0M | -- | $616.7M | $814.9M | -- | ||
| OPERATING INCOME | |||||||||
| Operating income | $-266.2M | $-474.5M | $-576.6M | $-512.2M | $-607.4M | $-593.0M | $-523.4M | ||
| EBITDA | $-274.8M | $-467.4M | $-533.8M | $-397.4M | $-565.5M | $-433.6M | $-663.1M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | $8.8M | $36.7M | $46.8M | $80.4M | $81.3M | $91.0M | $53.1M | ||
| Intinc | $8.9M | $4.0M | $1.1M | $7.5M | $18.0M | $17.2M | $19.9M | ||
| Net Non-Operating Interest Income/Expense | $150.0K | $-32.6M | $-45.6M | $-72.9M | $-63.3M | $-73.7M | $-33.2M | ||
| Gain on Sale of Securities | -- | -- | $2.2M | -- | -- | -- | -- | ||
| Other Income/Expense | $22.5M | $-1.6M | $-35.8M | $56.7M | $-17.4M | $-132.8M | $50.7M | ||
| Other Special Charges | $-1.6M | $1.6M | $35.8M | $-7.5M | $17.4M | $-14.3M | $21.9M | ||
| SPECIAL ITEMS | |||||||||
| Restructring And Mn A Income | -- | -- | -- | $43.8M | $7.9M | $15.6M | $21.3M | ||
| Special Income Charges | -- | -- | -- | $-43.8M | $-7.9M | $-15.6M | $-21.3M | ||
| Other Impairment Of Capital Assets | -- | -- | $2.6M | $12.7M | -- | $271.0K | -- | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-274.8M | $-468.8M | $-539.7M | $-404.2M | $-572.0M | $-451.2M | $-679.4M | ||
| Pre-Tax Income | $-283.6M | $-505.5M | $-580.2M | $-484.7M | $-653.3M | $-542.2M | $-732.5M | ||
| INCOME TAX | |||||||||
| Tax Provision | -- | -- | -- | -- | -- | $1.2M | $435.0K | ||
| NET INCOME | |||||||||
| Net Income | $-260.6M | $-448.7M | $-562.5M | $-481.2M | $-643.2M | $-535.8M | $-724.9M | ||
| Net Income (Continuing Operations) | $-283.6M | $-448.7M | $-562.5M | $-484.7M | $-653.3M | $-543.3M | $-732.9M | ||
| Net Income (Discontinued Operations) | $-260.6M | $-448.7M | $-562.5M | $-481.2M | $-643.2M | $-535.8M | $-724.9M | ||
| Net Income (Common Stockholders) | $-260.6M | $-448.7M | $-562.5M | $-481.2M | $-643.2M | $-535.8M | $-724.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-703.8M | ||
| TOTALS | |||||||||
| Total Expenses | $306.8M | $482.7M | $640.1M | $546.1M | $608.7M | $799.3M | $1.0B | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $105.1M | $118.0M | $144.4M | $147.5M | $162.8M | $186.1M | $191.5M | ||
| Average Shares Outstanding (Diluted) | $105.1M | $118.0M | $144.4M | $147.5M | $162.8M | $186.1M | $191.5M | ||
| Shares Outstanding | $123.8M | $149.0M | $147.6M | $151.4M | $175.8M | $190.2M | $193.9M | ||
| Basic EPS | $-2.48 | $-3.8 | $-3.9 | $-3.26 | $-3.95 | $-2.88 | $-3.78 | ||
| Basic EPS (Continuing Operations) | $-2.48 | $-3.8 | $-3.9 | $-3.26 | $-3.95 | $-2.88 | $-3.78 | ||
| Diluted EPS | $-2.48 | $-3.8 | $-3.9 | $-3.26 | $-3.95 | $-2.88 | $-3.78 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-3.26 | $-3.95 | $-2.88 | $-3.78 | ||
| OTHER METRICS | |||||||||
| Earnings from equity interest | $-20.9M | -- | -- | -- | -- | $-31.2M | $-72.6M | ||
| Earnings From Equity Interest Net Of Tax | $-20.9M | -- | -- | -- | -- | $-31.2M | $-72.6M | ||
| Gain On Sale Of Business | -- | -- | -- | -- | -- | $178.3M | -- | ||
| Interest Expense Operating | -- | -- | $29.3M | -- | -- | -- | -- | ||
| Minority Interests | $28.0M | $56.8M | $23.9M | $3.5M | $10.0M | $7.6M | $8.0M | ||
| Other Gand A | $94.4M | $145.7M | $192.2M | $143.2M | $150.6M | $288.9M | $531.2M | ||
| Rent And Landing Fees | $2.8M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | $43.8M | $7.9M | $15.6M | $21.3M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BBIO | $67.04 | -3.0% | 1.25M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |